Asia Pacific Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Chan

Asia Pacific Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)

The Asia Pacific sarcopenia treatment market was valued at US$ 696.85 million in 2022 and is expected to reach US$ 1,164.04 million by 2030; it is estimated to register a CAGR of 6.6% from 2022 to 2030.

Products in Clinical Trial Phases Drive Asia Pacific Sarcopenia Treatment Market

A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:

Table 1. Sarcopenia Drug Under Clinical Development
Company Name Interventions Conditions Clinical Trial Stage
Abbott Nutrition Medical Food with AN777
Oral Nutritional Formula Malnutrition
Sarcopenia PHASE3
Nutricia Research Dietary Supplement: Bolus ONS A
Dietary Supplement: Bolus ONS B
Dietary Supplement: Bolus ONS C
Dietary Supplement: Bolus ONS D Sarcopenia PHASE1
Novartis Pharmaceuticals Drug: Bimagrumab Sarcopenia PHASE2
McMaster University Behavioural: Step Reduction Sarcopenia PHASE1
Metabolic Technologies Inc. Dietary Supplement: Placebo
Drug: HMB Plus Vitamin D
Behavioural: Non-Exercise
Behavioural: Exercise Sarcopenia PHASE1
Merck Sharp & Dohme LLC Drug: Comparator MK-077
Drug: Comparator Placebo Sarcopenia PHASE2
Immunotec Inc. Dietary Supplement: Immunocal
Dietary Supplement: Casein Aging and Sarcopenia PHASE2
Lijun Yang Combination Product: 3-Month Intensive Intervention Sarcopenia PHASE4
Regeneron Pharmaceuticals Drug: REGN1033 (SAR391786)
Drug: Placebo Sarcopenia PHASE2
Source: Company Websites and The Insight Partners Analysis

Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.

Asia Pacific Sarcopenia Treatment Market Overview

The Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. Asia is the world's most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians led extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6-22.1%) than females (prevalence 7.7-21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research in Asia.

Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Sarcopenia Treatment Market Segmentation

The Asia Pacific sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the Asia Pacific sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

In terms of distribution channel, the Asia Pacific sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

By country, the Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Asia Pacific sarcopenia treatment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific sarcopenia treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific sarcopenia treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific sarcopenia treatment market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution. Show more